Tucatinib Plus Trastuzumab for Chemotherapy-Refractory, HER2+, RAS Wild-Type Unresectable or Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Lancet Oncol 2023 May 01;24(5)496-508, JH Strickler, A Cercek, S Siena, T André, K Ng, E Van Cutsem, C Wu, AS Paulson, JM Hubbard, AL Coveler, C Fountzilas, A Kardosh, PM Kasi, HJ Lenz, KK Ciombor, E Elez, DL Bajor, C Cremolini, F Sanchez, M Stecher, W Feng, TS Bekaii-SaabFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.